Publications

Genomic DNA transposition induced by human PGBD5

Genomic DNA transposition induced by human PGBD5

https://elifesciences.org/articles/10565

Henssen, A. G., Henaff, E., Jiang, E., Eisenberg, A., Carson, J. R., Villasante, C. M., Ray, M., Still, E., Burns, M., Gandara, J., Feschotte, C., Mason, C. E., Kentsis, A. “Genomic DNA transposition induced by human PGBD5.” eLife, 2015, Sep 25;4. pii: e10565

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=26631615

Henssen, A. G., Althoff, K., Odersky, A., Beckers, A., Koche, R., Speleman, F., Schäfers, S., Bell, E., Nortmeyer, M., Westermann, F., De Preter, K., Florin, A., Heukamp, L., Spruessel, A., Astrahanseff, K., Lindner, S., Sadowski, N., Schramm, A., Astorgues-Xerri, L., Riveiro, M. E., Eggert, A., Cvitkovic, E., Schulte, J. H. “Targeting MYCN-driven transcription by BET-bromodomain inhibition.” Clinical Cancer Research 2016, May 15; -22(10):247081.

Forward genetic screen of human transposase genomic rearrangements

Forward genetic screen of human transposase genomic rearrangements

https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-016-2877-x

Henssen, A. G., Jiang E., Zhuang J., Pinello L., Socci N.D., Koche R., Gonen M., Villasante C. M., Armstrong S. A., Bauer D. E., Weng Z., Kentsis A. “Forward genetic screen of human transposase genomic rearrangements.” BMC Genomics 2016, Aug 4;17:548.

PGBD5 promotes site-specific oncogenic mutations in human tumors

PGBD5 promotes site-specific oncogenic mutations in human tumors

https://www.nature.com/articles/ng.3866

Henssen, A.G., Koche, R. Zhuang J., Jiang E., Reed C., Eisenberg A., Still E., MacArthur I.C., Rodríguez-Fos E., Gonzalez S., Puiggròs M., Blackford A.N., Mason C.E., de Stanchina E., Gönen M., Emde A.K., Shah M., Arora K., Reeves C., Socci N.D., Perlman E., Antonescu C.R., Roberts C.W.M., Steen H., Mullen E., Jackson S.P., Torrents D., Weng Z., Armstrong, S.A. & Kentsis, A., “PGBD5 promotes site-specific oncogenic mutations in human tumors.” Nat. Genet. 2017, Jul;49(7):1005-1014.

Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors

Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors

http://stm.sciencemag.org/content/9/414/eaam9078

Henssen, A.G., Reed, C., Jiang, E., Dorado Garcia, H., von Stebut, J., MacArthur, I.C., Hundsdoerfer, P., Kim, J.H., de Stanchina, E., Kuwahara, Y., Hosoi, H., Ganem, N.J., Dela Cruz, F., Kung, A.L., Schulte, J.H., Petrini, J.H., Kentsis, A. “Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors”. Sci Transl Med, 2017, Nov 1;9(414).

Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma

Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma

https://www.sciencedirect.com/science/article/pii/S0304383518307274?via%3Dihub

Han, Y., Lindner, S., Bei, Y., Garcia, H.D., Timme, N., Althoff, K., Odersky, A., Schramm, A., Lissat, A., Künkele, A., Deubzer, H.E., Eggert, A., Schulte, J.H., Henssen A. G. “Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.” Cancer Lett. 2019 Jan 3. pii: S0304-3835(18)30727-4.

Mutational dynamics between primary and relapse neuroblastomas

Mutational dynamics between primary and relapse neuroblastomas

https://www.nature.com/articles/ng.3349

Schramm, A., Köster, J., Assenov, Y., Althoff, K., Peifer, M., Mahlow, E., Odersky, A., Beisser, D., Ernst, C., Henssen, A.G., Stephan, H., Schröder, C., Heukamp, L., Engesser, A., Kahlert, Y., Theissen, J., Hero, B., Roels, F., Altmüller, J., Nürnberg, P., Astrahantseff, K., Gloeckner, C., De Preter, K., Plass, C., Lee, S., Lode, H.N., Henrich, K.O., Gartlgruber, M., Speleman, F., Schmezer, P., Westermann, F., Rahmann, S., Fischer, M., Eggert, A., Schulte J. H. „Mutational dynamics between primary and relapse neuroblastomas“. Nat. Genet. 2015, Aug;47(8):872-7

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets

https://www.nature.com/articles/s41467-018-06699-9

Decaesteker, B., Denecker, G., Van Neste, C., Dolman, E.M., Van Loocke, W., Gartlgruber, M., Nunes, C., De Vloed, F., Depuydt, P., Verboom, K., Rombaut, D., Loontiens, S., De Wyn, J., Kholosy, W.M., Koopmans, B., Essing, A.H.W., Herrmann, C., Dreidax, D., Durinck, K., Deforce, D., van Nieuwerburgh, F., Henssen, A., Versteeg, R., Boeva, V., Schleiermacher, G., van Nes, J., Mestdagh, P., Vanhauwaert, S., Schulte, J.H., Westermann, F., Molenaar, J.J., De Preter, K., Speleman, F. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. Nat Commun. 2018 Nov 19;9(1):4866.